PharmTech Drug Digest 11.20
News|Videos|November 17, 2026

Challenges in Oral Delivery of Peptides: Scale Up

Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.

Oral peptide delivery has become a focus of developers moving into the peptide therapeutic market, especially those developing glucagon-like peptide-1 (GLP-1) products. However, these products often suffer from poor oral bioavailability.1 PharmTech spoke with Robert Sciscento, a senior scientist at Alcami Corporation, to find out more about the challenges of scaling up oral peptide products, and the outlook for oral GLP-1 therapies.

According to Sciscento, overcoming enzymatic degradation starts with the peptide itself. Peptides meant for oral delivery are often modified with end capping and amino acid substitutions, so an oral version may differ slightly from its injectable counterpart. Formulators can also design around a peptide’s specific degradation pathway. Enteric coatings, for example, may benefit a peptide that breaks down through acid hydrolysis. Polymer-based solid dispersions can also shield the peptide as it passes through the stomach and GI tract.

Scale-up brings its own challenges, says Sciscento. An oral dose may be higher than an injectable dose; therefore, making a batch of tablets takes far more active ingredient. Many peptides are also sensitive to moisture and need low-humidity or dry processing. That usually rules out wet granulation, leaving direct blending or dry granulation methods such as roller compaction. To guard against moisture, manufacturers can control humidity during processing, add a moisture-barrier coating to the formulation, and use protective packaging.

Sciscento sees the GLP-1 field as wide open when it comes to drug delivery. Most GLP-1 and other peptide products are currently benchmarked against subcutaneous or other parenteral forms. Moving a GLP-1 to a solid oral dose could cut costs significantly. Many programs are at an early stage, but Rybelsus shows the approach can succeed. Sciscento expects many companies to follow that model and offer the same drug in both injectable and oral forms where possible. Because tablets and capsules are much easier for patients to take, he believes they hold considerable value for GLP-1 therapies.

Click the video above to watch the interview.

Watch part 1 here.

Reference

  1. Challener C. Improving oral peptide delivery through structural modifications. PharmTech.com. November 2, 2026. https://www.pharmtech.com/view/improving-oral-peptide-delivery-through-structural-modifications

About the Speaker

Bobby Sciscento works at Alcami Corporation’s OSD facility located in Wilmington, NC as a Sr Scientist, Formulations. He holds a Master’s degree in Pharmaceutical Science from Campbell University. He has worked at Alcami for 5 years and in oral solid dose formulation development for 11 years. Bobby has supported multiple successful first in human IND applications and maintains a working knowledge of applying various drug development techniques to scalable industrial based formulations.


Related to this article